The ITIH2 Knockout A-549 Polyclonal Cells provide a CRISPR/Cas9-edited polyclonal knockout cell population targeting the ITIH2 gene in the human A-549 lung adenocarcinoma cell line. This product is generated through a non-clonal selection strategy, yielding a heterogeneous mixture of cells with targeted gene disruption. Compared to monoclonal knockout lines, the polyclonal approach maintains greater cellular diversity and minimizes artifacts arising from single-cell cloning, while still providing a robust loss-of-function model. The population is optimized for experiments that require substantial cell numbers or where clonal variation could obscure phenotype interpretation, enabling researchers to investigate the role of ITIH2 in extracellular matrix dynamics within a lung cancer context.
The A-549 host cell line originates from a lung carcinoma of a 58-year-old Caucasian male and is a well-established in vitro model of type II alveolar epithelial cells. These cells recapitulate key aspects of human pneumocyte biology and are extensively utilized in lung cancer research, drug metabolism studies, and respiratory disease modeling. The A-549 line??s documented genetic stability and phenotypical relevance to non-small cell lung cancer (NSCLC) make it an appropriate platform for studying tumor biology, particularly in relation to extracellular matrix interactions and inflammatory signaling.
ITIH2 encodes heavy chain 2 of the inter-alpha-trypsin inhibitor (I??I) family, a serine protease inhibitor critical for hyaluronan-rich matrix stabilization. ITIH2 is covalently incorporated into hyaluronan via TSG-6 (TNFAIP6) catalytic activity, crosslinking hyaluronan chains. Its expression responds to IL-6, TNF-alpha, and TGF-beta, integrating inflammatory signals. Within the I??I complex, ITIH2 associates with bikunin (AMBP) and other heavy chains (ITIH1, ITIH3), interacting with CD44 to transmit matrix signals. Downstream, ITIH2 influences hyaluronan synthase 2 (HAS2) and matrix metalloproteinases (MMPs), regulating pericellular matrix turnover and cell adhesion.
Disruption of ITIH2 in A-549 cells is expected to impair the formation of stable hyaluronan matrices, perturbing crucial cell-matrix interactions that govern tumor cell behavior. Given the established link between hyaluronan deposition and poor prognosis in NSCLC, this knockout model offers a direct tool to examine how loss of ITIH2-mediated matrix stabilization affects metastatic potential and inflammatory responses. The polyclonal population allows for the assessment of heterogeneous phenotypic responses, reflecting the clonal diversity naturally present in tumors. Consequently, this system is particularly suited to uncovering the contributions of ECM remodeling to the aggressive properties of lung adenocarcinoma cells, including invasion and resistance to apoptosis.
Researchers can utilize this model for tumor microenvironment investigations, including migration and invasion assays to assess metastatic potential. The hyaluronan particle exclusion assay and immunofluorescence staining allow direct examination of matrix architecture. RT-qPCR and western blotting can quantify MMP and HAS2 expression changes, while flow cytometry detects CD44 presentation. These tools are valuable for studying ECM remodeling in lung cancer and matrix-mediated inflammatory signaling within the complement cascade context. For further product details, please contact Ascent Research.
